MicroPort Endovascular MedTech Ltd (688016) - Total Assets
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) holds total assets worth CN¥4.79 Billion CNY (≈ $701.48 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 688016 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
MicroPort Endovascular MedTech Ltd - Total Assets Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's total assets have evolved over time, based on quarterly financial data. See MicroPort Endovascular MedTech Ltd (688016) net assets for net asset value and shareholders' equity analysis.
MicroPort Endovascular MedTech Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
MicroPort Endovascular MedTech Ltd's total assets of CN¥4.79 Billion consist of 60.4% current assets and 39.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 43.2% |
| Accounts Receivable | CN¥368.08 Million | 7.9% |
| Inventory | CN¥272.30 Million | 5.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥603.25 Million | 13.0% |
| Goodwill | CN¥465.25 Million | 10.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of MicroPort Endovascular MedTech Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MicroPort Endovascular MedTech Ltd's current assets represent 60.4% of total assets in 2025, an increase from 40.4% in 2016.
- Cash Position: Cash and equivalents constituted 43.2% of total assets in 2025, up from 14.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, a decrease from 27.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 13.0% of total assets.
MicroPort Endovascular MedTech Ltd Competitors by Total Assets
Key competitors of MicroPort Endovascular MedTech Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
|
ORTOMA AB B
F:82Y
|
Germany | €161.34 Million |
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM
|
USA | $101.85 Million |
|
Allmed Solutions Ltd
TA:ALMD
|
Israel | ILA31.54 Million |
|
Universal Biosensors Inc
AU:UBI
|
Australia | AU$14.94 Million |
MicroPort Endovascular MedTech Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.94 | 6.28 | 10.32 |
| Quick Ratio | 6.27 | 5.77 | 9.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.52 Billion | CN¥2.42 Billion | CN¥1.18 Billion |
MicroPort Endovascular MedTech Ltd - Advanced Valuation Insights
This section examines the relationship between MicroPort Endovascular MedTech Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 8.1% |
| Total Assets | CN¥4.64 Billion |
| Market Capitalization | $1.65 Billion USD |
Valuation Analysis
Below Book Valuation: The market values MicroPort Endovascular MedTech Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: MicroPort Endovascular MedTech Ltd's assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual total assets of MicroPort Endovascular MedTech Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.64 Billion ≈ $679.15 Million |
+8.15% |
| 2024-12-31 | CN¥4.29 Billion ≈ $628.00 Million |
+1.07% |
| 2023-12-31 | CN¥4.25 Billion ≈ $621.35 Million |
+112.83% |
| 2022-12-31 | CN¥2.00 Billion ≈ $291.95 Million |
+13.77% |
| 2021-12-31 | CN¥1.75 Billion ≈ $256.60 Million |
+27.43% |
| 2020-12-31 | CN¥1.38 Billion ≈ $201.36 Million |
+19.07% |
| 2019-12-31 | CN¥1.16 Billion ≈ $169.12 Million |
+329.93% |
| 2018-12-31 | CN¥268.82 Million ≈ $39.34 Million |
+19.87% |
| 2017-12-31 | CN¥224.26 Million ≈ $32.82 Million |
+18.91% |
| 2016-12-31 | CN¥188.60 Million ≈ $27.60 Million |
-- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more